Huapont Life Sciences Co Ltd
SZSE:002004
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (13.3), the stock would be worth ¥2.32 (57% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 30.9 | ¥5.41 |
0%
|
| 3-Year Average | 13.3 | ¥2.32 |
-57%
|
| 5-Year Average | 11.5 | ¥2.02 |
-63%
|
| Industry Average | 38.3 | ¥6.69 |
+24%
|
| Country Average | 28.9 | ¥5.06 |
-7%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Huapont Life Sciences Co Ltd
SZSE:002004
|
10.7B CNY | 30.9 | -77 | |
| US |
|
Corteva Inc
NYSE:CTVA
|
53.6B USD | 19.1 | 48.7 | |
| CA |
|
Nutrien Ltd
TSX:NTR
|
47.7B CAD | 12.3 | 14.9 | |
| CN |
|
Qinghai Salt Lake Industry Co Ltd
SZSE:000792
|
188.9B CNY | 24.2 | 22.7 | |
| CL |
|
Sociedad Quimica y Minera de Chile SA
NYSE:SQM
|
25.4B USD | 27.6 | 43.2 | |
| CN |
|
Zangge Mining Co Ltd
SZSE:000408
|
137.1B CNY | 81.3 | 29.3 | |
| US |
|
CF Industries Holdings Inc
NYSE:CF
|
18.6B USD | 8.5 | 12.8 | |
| NO |
|
Yara International ASA
OSE:YAR
|
136.8B NOK | 10 | 10.5 | |
| SA |
|
SABIC Agri-Nutrients Company SJSC
SAU:2020
|
53.8B SAR | 10 | 12.4 | |
| RU |
|
PhosAgro PAO
MOEX:PHOR
|
912.2B RUB | 6 | 7.9 | |
| CN |
|
Shandong Hualu-Hengsheng Chemical Co Ltd
SSE:600426
|
77.1B CNY | 18.6 | 23.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.6 |
| Median | 28.9 |
| 70th Percentile | 52.9 |
| Max | 49 021 |
Other Multiples
Huapont Life Sciences Co Ltd
Glance View
Huapont Life Sciences Co., Ltd., a prominent player in the global pharmaceutical and agrochemical sector, finds its roots in the bustling city of Chongqing, China. Established in 1992, the company swiftly evolved from a regional upstart to a substantial force in the life sciences industry. Huapont's narrative is grounded in its strategic blend of pharmaceutical prowess and agrochemical dexterity. The company's pharmaceutical operations primarily focus on the development, production, and marketing of dermatological and anti-tuberculosis drugs, riding on China's expansive healthcare reforms and increasing demand for specialized medical treatments. This niche approach allows Huapont to capture a substantial share of the market, offering innovative solutions that cater to rising public health concerns. Parallel to its medical endeavors, Huapont has cultivated a robust agrochemical arm. The company leverages advanced research and development to produce and distribute a wide range of crop protection products, including herbicides, fungicides, and insecticides. This diversification in agrochemicals keeps Huapont resilient amidst agricultural cycles and global market fluctuations, providing a steady stream of revenue. By interweaving pharmaceutical advancements with agricultural science, Huapont effectively taps into two essential human needs: health and sustenance. Through these dual pillars, the company harmoniously balances its portfolio, drawing upon scientific research and market insights to drive sustainable growth and enduring value for its stakeholders.